Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2020 | The second COMy meeting of the year: new multiple myeloma data

Saad Usmani • 5 Oct 2020
COMy 2020
Multiple Myeloma

Saad Usmani, MD, University of North Carolina School of Medicine, Chapel Hill, NC, discusses the successes of the COMy meeting. Since the last virtual meeting in May, there has been new data to highlight and discuss. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.

Disclosures

Saad Z. Usmani reports consulting for Abbvie, Amgen, BMS, Celgene, GSK, Janssen, Merck, Takeda, Sanofi and SkylineDx; speaker’s fees for Amgen, Celgene, Janssen, Sanofi and Takeda; and research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda.

More from Saad Usmani

1:14
Clinical benefit of teclistamab vs real-world physician’s choice for R/R multiple myeloma
Saad Usmani • 8 Sep 2023
1:53
MajesTEC‐1 update: rates of infection in patients with myeloma receiving teclistamab
Saad Usmani • 8 Sep 2023
1:43
High-risk multiple myeloma: addressing challenges and unmet needs
Saad Usmani • 8 Sep 2023
2:05
Exciting ongoing trials in frontline transplant-eligible patients with multiple myeloma
Saad Usmani • 25 Aug 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals